Catawba Capital Management VA decreased its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 16.9% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,300 shares of the biotechnology company’s stock after selling 670 shares during the period. Catawba Capital Management VA’s holdings in BioMarin Pharmaceutical were worth $294,000 at the end of the most recent reporting period.

Other institutional investors also recently added to or reduced their stakes in the company. State of Alaska Department of Revenue boosted its holdings in shares of BioMarin Pharmaceutical by 233.1% during the fourth quarter. State of Alaska Department of Revenue now owns 18,691 shares of the biotechnology company’s stock worth $1,666,000 after purchasing an additional 13,080 shares during the last quarter. Frontier Capital Management Co. LLC boosted its holdings in shares of BioMarin Pharmaceutical by 9.5% during the fourth quarter. Frontier Capital Management Co. LLC now owns 828,666 shares of the biotechnology company’s stock worth $73,892,000 after purchasing an additional 72,120 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its holdings in shares of BioMarin Pharmaceutical by 4.8% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 335,899 shares of the biotechnology company’s stock worth $29,953,000 after purchasing an additional 15,414 shares during the last quarter. Creative Planning boosted its holdings in shares of BioMarin Pharmaceutical by 52.4% during the fourth quarter. Creative Planning now owns 6,192 shares of the biotechnology company’s stock worth $552,000 after purchasing an additional 2,129 shares during the last quarter. Finally, Gateway Investment Advisers LLC acquired a new stake in shares of BioMarin Pharmaceutical during the fourth quarter worth $863,000. 99.15% of the stock is owned by institutional investors.

Several research firms have recently issued reports on BMRN. Zacks Investment Research cut BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a report on Wednesday. Credit Suisse Group restated an “outperform” rating and set a $113.00 price objective on shares of BioMarin Pharmaceutical in a report on Thursday. Piper Jaffray Companies restated a “buy” rating and set a $114.00 price objective on shares of BioMarin Pharmaceutical in a report on Thursday. BidaskClub cut BioMarin Pharmaceutical from a “sell” rating to a “strong sell” rating in a report on Saturday. Finally, Leerink Swann restated an “outperform” rating and set a $142.00 price objective (up previously from $136.00) on shares of BioMarin Pharmaceutical in a report on Thursday, October 19th. Two analysts have rated the stock with a sell rating, eight have given a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. BioMarin Pharmaceutical presently has a consensus rating of “Buy” and an average price target of $111.69.

In other BioMarin Pharmaceutical news, EVP George Eric Davis sold 1,200 shares of the business’s stock in a transaction dated Thursday, November 30th. The stock was sold at an average price of $85.64, for a total transaction of $102,768.00. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Henry J. Fuchs sold 15,000 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $89.23, for a total value of $1,338,450.00. The disclosure for this sale can be found here. Insiders sold 60,750 shares of company stock worth $5,439,788 in the last quarter. 1.85% of the stock is owned by insiders.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) opened at $89.12 on Friday. BioMarin Pharmaceutical Inc. has a fifty-two week low of $80.10 and a fifty-two week high of $100.51. The company has a debt-to-equity ratio of 0.41, a current ratio of 4.91 and a quick ratio of 3.81.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its earnings results on Thursday, October 26th. The biotechnology company reported ($0.07) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.13) by $0.06. BioMarin Pharmaceutical had a negative return on equity of 4.60% and a negative net margin of 12.45%. The firm had revenue of $334.18 million for the quarter, compared to analysts’ expectations of $347.38 million. During the same quarter last year, the firm earned $0.02 earnings per share. The firm’s revenue for the quarter was up 19.4% compared to the same quarter last year. analysts anticipate that BioMarin Pharmaceutical Inc. will post -0.64 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This news story was published by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another domain, it was stolen and reposted in violation of United States & international trademark and copyright law. The original version of this news story can be viewed at https://www.watchlistnews.com/catawba-capital-management-va-sells-670-shares-of-biomarin-pharmaceutical-inc-bmrn/1815010.html.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).

Institutional Ownership by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.